Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of ...
Recent Clinical Progress, Enrollment Achievements, Expanded Intellectual Property Portfolio and Strengthened Financial Position Support a Potentially Transformative 12-Month Value Creation Opportunity ...
The planned Phase 3 trial in approximately 750 postmenopausal women with osteoporosis, with a primary endpoint of total hip bone mineral density ...
LLVM powers the core development tools, operating systems, and most applications at Apple Computer, where it long ago ...
After losing civil service protections, some federal employees now in Schedule Policy/Career fear for their job security and retribution for speaking up.
St. Louis will host July workshops and a virtual meeting to present draft zoning development standards, share map updates, ...
Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it has begun treating patients in RASolute 305, ...
PARP inhibitors reshaped oncology when they first reached patients some 10 years ago, but they represent just one entry point into a much larger and more intricate biological network.
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has completed enrollment in the pivotal cohort (Cohort 1) of the global Phase 3 REVEAL study evaluating obudanersen (ION582), an ...
Explore the evolving landscape of male contraception, including novel nonhormonal pills and injectable hydrogels in clinical ...
The new agreement creates more competition but could leave officials "looking over their shoulders." ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results